Angelo Paredes, MD
Gastroenterology · Middletown, CTNPI 1235289398
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Echosens North America, Inc. at 27.3% of the total. 2025 is the largest year on record at $10,629, more than ten times the $123 reported in 2019.
Across 589 payments — averaging $39.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Echosens North America, Inc.$6K
- Madrigal Pharmaceuticals$5K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Gilead$858
- plus $5K from 29 others
Across 90 payments — averaging $14,222 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$942K
- AbbVie$208K
- Intercept Pharma Europe Ltd.$81K
- Bristol Myers Squibb$43K
- E.r. Squibb & Sons, L.L.C.$5K
- Gilead$675
What the payments were for
- Consulting fees$6,93030%
- Speaking & faculty fees$3,60016%
- Travel & lodging$2051%
- Food & beverage$12,22453%
- Education$300%
- Other$820%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Echosens North America, Inc. | 9 | $6,300 |
| Madrigal Pharmaceuticals | 15 | $4,990 |
| AbbVie | 124 | $2,311 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 101 | $1,918 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $1,301 |
| Gilead | 40 | $858 |
| Bristol Myers Squibb | 51 | $845 |
| Ardelyx, Inc. | 27 | $591 |
| Johnson & Johnson(2 entities) | 25 | $515 |
| QOL Medical, LLC | 18 | $457 |
| Intercept Pharmaceuticals, Inc. | 17 | $373 |
| Regeneron Healthcare Solutions, Inc. | 11 | $234 |
| Pfizer | 12 | $230 |
| Redhill Biopharma Inc. | 10 | $180 |
| Aimmune Therapeutics, Inc. | 6 | $172 |
| Ironwood Pharmaceuticals, Inc | 8 | $170 |
| Sanofi | 7 | $168 |
| Mallinckrodt Hospital Products Inc. | 2 | $157 |
| Organon | 7 | $138 |
| Braintree Laboratories, Inc. | 7 | $130 |
| Nestle Healthcare Nutrition Inc. | 7 | $124 |
| Dova Pharmaceuticals | 1 | $123 |
| Medtronic | 1 | $104 |
| Ferring Pharmaceuticals Inc. | 7 | $102 |
| Phathom Pharmaceuticals, Inc. | 5 | $85 |
| Pentax Of America, Inc. | 1 | $82 |
| Boston Scientific | 1 | $76 |
| Lilly USA, LLC | 4 | $73 |
| Celltrion USA Inc. | 2 | $51 |
| Amgen | 2 | $48 |
| Exact Sciences | 2 | $42 |
| Novo Nordisk | 2 | $42 |
| Lucid Diagnostics Inc. | 2 | $39 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,071 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 32 | $125,766 |
| RinvoqUpadacitinib | 11 | $115,583 |
| LinzessLinaclotide | 37 | $41,191 |
| Mesalamine | 20 | $10,102 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 113 | $6,587 |
| Famotidine | 201 | $4,308 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,819 |
| Pantoprazole Sodium | 231 | $2,807 |
| Sucralfate | 13 | $2,807 |
| Esomeprazole Magnesium | 45 | $1,642 |
| CholestyramineCholestyramine (With Sugar) | 15 | $698 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 40 | $440 |
| Omeprazole | 13 | $317 |
| Lactulose | 11 | $230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $2,311 | $156,77448 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,918 | $125,76632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Middletown
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
- Michael EinsteinHartford$139K
- Pramod MistryNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.